Marina Noris

List of Publications by Citations

208 papers	15,826 citations	66 h-index	122 g-index
222 ext. papers	18,023 ext. citations	8.7 avg, IF	6.54 L-index

#	Paper	IF	Citations
208	Atypical hemolytic-uremic syndrome. *New England Journal of Medicine*, **2009**, 361, 1676-87	59.2	934
207	Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. *Clinical Journal of the American Society of Nephrology: CJASN*, **2010**, 5, 1844-59	6.9	661
206	Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome. *Blood*, **2006**, 108, 1267-79	2.2	561
205	Thrombomodulin mutations in atypical hemolytic-uremic syndrome. *New England Journal of Medicine*, **2009**, 361, 345-57	59.2	418
204	Overview of complement activation and regulation. *Seminars in Nephrology*, **2013**, 33, 479-92	4.8	415
203	Hemolytic uremic syndrome. *Journal of the American Society of Nephrology: JASN*, **2005**, 16, 1035-50	12.7	390
202	Nitric oxide synthesis by cultured endothelial cells is modulated by flow conditions. *Circulation Research*, **1995**, 76, 536-43	15.7	371
201	Pretransplant infusion of mesenchymal stem cells prolongs the survival of a semiallogeneic heart transplant through the generation of regulatory T cells. *Journal of Immunology*, **2008**, 181, 3933-46	5.3	370
200	Thrombotic microangiopathy, hemolytic uremic syndrome, and thrombotic thrombocytopenic purpura. *Kidney International*, **2001**, 60, 831-46	9.9	325
199	STEC-HUS, atypical HUS and TTP are all diseases of complement activation. *Nature Reviews Nephrology*, **2012**, 8, 622-33	14.9	275
198	Familial haemolytic uraemic syndrome and an MCP mutation. *Lancet, The*, **2003**, 362, 1542-7	40	268
197	Mutations in factor H reduce binding affinity to C3b and heparin and surface attachment to endothelial cells in hemolytic uremic syndrome. *Journal of Clinical Investigation*, **2003**, 111, 1181-90	15.9	267
196	Complement factor H mutations and gene polymorphisms in haemolytic uraemic syndrome: the C-257T, the A2089G and the G2881T polymorphisms are strongly associated with the disease. *Human Molecular Genetics*, **2003**, 12, 3385-95	5.6	260
195	Combined complement gene mutations in atypical hemolytic uremic syndrome influence clinical phenotype. *Journal of the American Society of Nephrology: JASN*, **2013**, 24, 475-86	12.7	254
194	Autologous mesenchymal stromal cells and kidney transplantation: a pilot study of safety and clinical feasibility. *Clinical Journal of the American Society of Nephrology: CJASN*, **2011**, 6, 412-22	6.9	231
193	Dynamics of complement activation in aHUS and how to monitor eculizumab therapy. *Blood*, **2014**, 124, 1715-26	2.2	220
192	The molecular basis of familial hemolytic uremic syndrome: mutation analysis of factor H gene reveals a hot spot in short consensus repeat 20. *Journal of the American Society of Nephrology: JASN* , **2001**, 12, 297-307	12.7	219

191	Mechanisms of disease: Pre-eclampsia. *Nature Clinical Practice Nephrology*, **2005**, 1, 98-114; quiz 120		217
190	Factor H family proteins: on complement, microbes and human diseases. *Biochemical Society Transactions*, **2002**, 30, 971-8	5.1	216
189	Regulatory T cells and T cell depletion: role of immunosuppressive drugs. *Journal of the American Society of Nephrology: JASN*, **2007**, 18, 1007-18	12.7	202
188	MYO1E mutations and childhood familial focal segmental glomerulosclerosis. *New England Journal of Medicine*, **2011**, 365, 295-306	59.2	195
187	Alternative pathway activation of complement by Shiga toxin promotes exuberant C3a formation that triggers microvascular thrombosis. *Journal of Immunology*, **2011**, 187, 172-80	5.3	186
186	von Willebrand factor cleaving protease (ADAMTS13) is deficient in recurrent and familial thrombotic thrombocytopenic purpura and hemolytic uremic syndrome. *Blood*, **2002**, 100, 778-85	2.2	183
185	The case of complement activation in COVID-19 multiorgan impact. *Kidney International*, **2020**, 98, 314-322	9.9	182
184	Interleukin-6 and RANTES in Takayasu arteritis: a guide for therapeutic decisions?. *Circulation*, **1999**, 100, 55-60	16.7	181
183	Atypical aHUS: State of the art. *Molecular Immunology*, **2015**, 67, 31-42	4.3	177
182	Outcome of renal transplantation in patients with non-Shiga toxin-associated hemolytic uremic syndrome: prognostic significance of genetic background. *Clinical Journal of the American Society of Nephrology: CJASN*, **2006**, 1, 88-99	6.9	172
181	Thrombotic microangiopathy after kidney transplantation. *American Journal of Transplantation*, **2010**, 10, 1517-23	8.7	161
180	Complement and the atypical hemolytic uremic syndrome in children. *Pediatric Nephrology*, **2008**, 23, 1957-72	3.2	161
179	Uremic Bleeding: Closing the Circle After 30 Years of Controversies?. *Blood*, **1999**, 94, 2569-2574	2.2	158
178	The interactive Factor H-atypical hemolytic uremic syndrome mutation database and website: update and integration of membrane cofactor protein and Factor I mutations with structural models. *Human Mutation*, **2007**, 28, 222-34	4.7	142
177	Enhanced nitric oxide synthesis in uremia: implications for platelet dysfunction and dialysis hypotension. *Kidney International*, **1993**, 44, 445-50	9.9	142
176	Liver-kidney transplantation to cure atypical hemolytic uremic syndrome. *Journal of the American Society of Nephrology: JASN*, **2009**, 20, 940-9	12.7	139
175	Combined kidney and liver transplantation for familial haemolytic uraemic syndrome. *Lancet, The*, **2002**, 359, 1671-2	40	139
174	Mesenchymal stromal cells and kidney transplantation: pretransplant infusion protects from graft dysfunction while fostering immunoregulation. *Transplant International*, **2013**, 26, 867-78	3	129

173	Localization of mesenchymal stromal cells dictates their immune or proinflammatory effects in kidney transplantation. *American Journal of Transplantation*, **2012**, 12, 2373-83	8.7	126
172	L-arginine depletion in preeclampsia orients nitric oxide synthase toward oxidant species. *Hypertension*, **2004**, 43, 614-22	8.5	124
171	Eculizumab in a patient with dense-deposit disease. *New England Journal of Medicine*, **2012**, 366, 1161-3	59.2	119
170	Membrane cofactor protein mutations in atypical hemolytic uremic syndrome (aHUS), fatal Stx-HUS, C3 glomerulonephritis, and the HELLP syndrome. *Blood*, **2008**, 111, 624-32	2.2	116
169	Complement factor H mutation in familial thrombotic thrombocytopenic purpura with ADAMTS13 deficiency and renal involvement. *Journal of the American Society of Nephrology: JASN*, **2005**, 16, 1177-83	12.7	116
168	Characterization of mutations in complement factor I (CFI) associated with hemolytic uremic syndrome. *Molecular Immunology*, **2008**, 45, 95-105	4.3	113
167	Hypocomplementemia discloses genetic predisposition to hemolytic uremic syndrome and thrombotic thrombocytopenic purpura: role of factor H abnormalities. Italian Registry of Familial and Recurrent Hemolytic Uremic Syndrome/Thrombotic Thrombocytopenic Purpura. *Journal of the American Society of Nephrology: JASN*, **1999**, 10, 281-93	12.7	113
166	Renal and systemic nitric oxide synthesis in rats with renal mass reduction. *Kidney International*, **1997**, 52, 171-81	9.9	112
165	C3 glomerulopathy - understanding a rare complement-driven renal disease. *Nature Reviews Nephrology*, **2019**, 15, 129-143	14.9	109
164	Hemolytic uremic syndrome: a fatal outcome after kidney and liver transplantation performed to correct factor h gene mutation. *American Journal of Transplantation*, **2005**, 5, 1146-50	8.7	109
163	Inhibition of the chemokine receptor CXCR2 prevents kidney graft function deterioration due to ischemia/reperfusion. *Kidney International*, **2005**, 67, 1753-61	9.9	107
162	Implications of the initial mutations in membrane cofactor protein (MCP; CD46) leading to atypical hemolytic uremic syndrome. *Molecular Immunology*, **2007**, 44, 111-22	4.3	105
161	Hemolytic Uremic Syndrome in Pregnancy and Postpartum. *Clinical Journal of the American Society of Nephrology: CJASN*, **2017**, 12, 1237-1247	6.9	104
160	Glomerular Diseases Dependent on Complement Activation, Including Atypical Hemolytic Uremic Syndrome, Membranoproliferative Glomerulonephritis, and C3 Glomerulopathy: Core Curriculum 2015. *American Journal of Kidney Diseases*, **2015**, 66, 359-75	7.4	103
159	Binding of complement factor H to endothelial cells is mediated by the carboxy-terminal glycosaminoglycan binding site. *American Journal of Pathology*, **2005**, 167, 1173-81	5.8	100
158	Hemolytic uremic syndrome. *Seminars in Immunopathology*, **2014**, 36, 399-420	12	96
157	Mutations in FN1 cause glomerulopathy with fibronectin deposits. *Proceedings of the National Academy of Sciences of the United States of America*, **2008**, 105, 2538-43	11.5	96
156	Residual plasmatic activity of ADAMTS13 is correlated with phenotype severity in congenital thrombotic thrombocytopenic purpura. *Blood*, **2012**, 120, 440-8	2.2	91

155	Statistical Validation of Rare Complement Variants Provides Insights into the Molecular Basis of Atypical Hemolytic Uremic Syndrome and C3 Glomerulopathy. *Journal of Immunology*, **2018**, 200, 2464-2478	5.3	89
154	Human mesenchymal stromal cells transplanted into mice stimulate renal tubular cells and enhance mitochondrial function. *Nature Communications*, **2017**, 8, 983	17.4	85
153	Complement gene variants determine the risk of immunoglobulin-associated MPGN and C3 glomerulopathy and predict long-term renal outcome. *Molecular Immunology*, **2016**, 71, 131-142	4.3	84
152	Sirolimus versus cyclosporine therapy increases circulating regulatory T cells, but does not protect renal transplant patients given alemtuzumab induction from chronic allograft injury. *Transplantation*, **2007**, 84, 956-64	1.8	84
151	Mapping interactions between complement C3 and regulators using mutations in atypical hemolytic uremic syndrome. *Blood*, **2015**, 125, 2359-69	2.2	79
150	Complement activation: the missing link between ADAMTS-13 deficiency and microvascular thrombosis of thrombotic microangiopathies. *Thrombosis and Haemostasis*, **2005**, 93, 443-52	7	75
149	Complement factor B mutations in atypical hemolytic uremic syndrome-disease-relevant or benign?. *Journal of the American Society of Nephrology: JASN*, **2014**, 25, 2053-65	12.7	74
148	Proteasomal processing of albumin by renal dendritic cells generates antigenic peptides. *Journal of the American Society of Nephrology: JASN*, **2009**, 20, 123-30	12.7	74
147	The complement factor H R1210C mutation is associated with atypical hemolytic uremic syndrome. *Journal of the American Society of Nephrology: JASN*, **2008**, 19, 639-46	12.7	73
146	A Genome-Wide Association Study of Diabetic Kidney Disease in Subjects With Type 2 Diabetes. *Diabetes*, **2018**, 67, 1414-1427	0.9	71
145	A novel atypical hemolytic uremic syndrome-associated hybrid CFHR1/CFH gene encoding a fusion protein that antagonizes factor H-dependent complement regulation. *Journal of the American Society of Nephrology: JASN*, **2015**, 26, 209-19	12.7	69
144	Effect of acetate, bicarbonate dialysis, and acetate-free biofiltration on nitric oxide synthesis: implications for dialysis hypotension. *American Journal of Kidney Diseases*, **1998**, 32, 115-24	7.4	67
143	The role of complement in C3 glomerulopathy. *Molecular Immunology*, **2015**, 67, 21-30	4.3	65
142	In-vitro and in-vivo consequences of mutations in the von Willebrand factor cleaving protease ADAMTS13 in thrombotic thrombocytopenic purpura. *Thrombosis and Haemostasis*, **2006**, 96, 454-464	7	64
141	Toward MSC in solid organ transplantation: 2008 position paper of the MISOT study group. *Transplantation*, **2009**, 88, 614-9	1.8	58
140	Effect of acetate-free biofiltration and bicarbonate hemodialysis on neutrophil activation. *American Journal of Kidney Diseases*, **2002**, 40, 783-93	7.4	57
139	In kidney transplant patients, alemtuzumab but not basiliximab/low-dose rabbit anti-thymocyte globulin induces B cell depletion and regeneration, which associates with a high incidence of de novo donor-specific anti-HLA antibody development. *Journal of Immunology*, **2013**, 191, 2818-28	5.3	56
138	Thymic dendritic cells express inducible nitric oxide synthase and generate nitric oxide in response to self- and alloantigens. *Journal of Immunology*, **2000**, 164, 4649-58	5.3	55

137	Dramatic effects of eculizumab in a child with diffuse proliferative lupus nephritis resistant to conventional therapy. *Pediatric Nephrology*, **2015**, 30, 167-72	3.2	54
136	Complement-mediated dysfunction of glomerular filtration barrier accelerates progressive renal injury. *Journal of the American Society of Nephrology: JASN*, **2008**, 19, 1158-67	12.7	54
135	Propionyl-L-carnitine prevents renal function deterioration due to ischemia/reperfusion. *Kidney International*, **2002**, 61, 1064-78	9.9	54
134	Rituximab prevents recurrence of thrombotic thrombocytopenic purpura: a case report. *Blood*, **2005**, 106, 925-8	2.2	52
133	Screening for complement system abnormalities in patients with atypical hemolytic uremic syndrome. *Clinical Journal of the American Society of Nephrology: CJASN*, **2007**, 2, 591-6	6.9	51
132	Systemic and fetal-maternal nitric oxide synthesis in normal pregnancy and pre-eclampsia. *BJOG: an International Journal of Obstetrics and Gynaecology*, **1996**, 103, 879-86	3.7	51
131	Extracellular vesicles derived from T regulatory cells suppress T cell proliferation and prolong allograft survival. *Scientific Reports*, **2017**, 7, 11518	4.9	49
130	Hemolytic uremic syndrome: a factor H mutation (E1172Stop) causes defective complement control at the surface of endothelial cells. *Journal of the American Society of Nephrology: JASN*, **2007**, 18, 506-14	12.7	49
129	Cluster Analysis Identifies Distinct Pathogenetic Patterns in C3 Glomerulopathies/Immune Complex-Mediated Membranoproliferative GN. *Journal of the American Society of Nephrology: JASN* , **2018**, 29, 283-294	12.7	48
128	Managing and preventing atypical hemolytic uremic syndrome recurrence after kidney transplantation. *Current Opinion in Nephrology and Hypertension*, **2013**, 22, 704-12	3.5	47
127	Atypical haemolytic uraemic syndrome with underlying glomerulopathies. A case series and a review of the literature. *Nephrology Dialysis Transplantation*, **2013**, 28, 2246-59	4.3	47
126	Where next with atypical hemolytic uremic syndrome?. *Molecular Immunology*, **2007**, 44, 3889-900	4.3	47
125	Cardiovascular complications in atypical haemolytic uraemic syndrome. *Nature Reviews Nephrology*, **2014**, 10, 174-80	14.9	46
124	Mycophenolate mofetil combined with a cyclooxygenase-2 inhibitor ameliorates murine lupus nephritis. *Kidney International*, **2001**, 60, 653-63	9.9	45
123	Sequential monitoring of urine-soluble interleukin 2 receptor and interleukin 6 predicts acute rejection of human renal allografts before clinical or laboratory signs of renal dysfunction. *Transplantation*, **1997**, 63, 1508-14	1.8	45
122	The Toll-IL-1R member Tir8/SIGIRR negatively regulates adaptive immunity against kidney grafts. *Journal of Immunology*, **2009**, 183, 4249-60	5.3	44
121	Thrombotic thrombocytopenic purpura--then and now. *Seminars in Thrombosis and Hemostasis*, **2006**, 32, 81-9	5.3	43
120	Vasopeptidase inhibitor restores the balance of vasoactive hormones in progressive nephropathy. *Kidney International*, **2004**, 66, 1959-65	9.9	43

119	Two patients with history of STEC-HUS, posttransplant recurrence and complement gene mutations. *American Journal of Transplantation*, **2013**, 13, 2201-6	8.7	42
118	Increased Fragmentation of von Willebrand Factor, Due to Abnormal Cleavage of the Subunit, Parallels Disease Activity in Recurrent Hemolytic Uremic Syndrome and Thrombotic Thrombocytopenic Purpura and Discloses Predisposition in Families. *Blood*, **1999**, 94, 610-620	2.2	42
117	Increased nitric oxide formation in recurrent thrombotic microangiopathies: a possible mediator of microvascular injury. *American Journal of Kidney Diseases*, **1996**, 27, 790-6	7.4	42
116	Renoprotection by nitric oxide donor and lisinopril in the remnant kidney model. *American Journal of Kidney Diseases*, **1999**, 33, 746-53	7.4	40
115	Characterization of a New DGKE Intronic Mutation in Genetically Unsolved Cases of Familial Atypical Hemolytic Uremic Syndrome. *Clinical Journal of the American Society of Nephrology: CJASN*, **2015**, 10, 1011-9	6.9	39
114	Podocyte dysfunction in atypical haemolytic uraemic syndrome. *Nature Reviews Nephrology*, **2015**, 11, 245-52	14.9	38
113	Variations of the angiotensin II type 1 receptor gene are associated with extreme human longevity. *Age*, **2013**, 35, 993-1005		38
112	Interaction between Multimeric von Willebrand Factor and Complement: A Fresh Look to the Pathophysiology of Microvascular Thrombosis. *Journal of Immunology*, **2017**, 199, 1021-1040	5.3	37
111	Atypical hemolytic uremic syndrome associated with mutations in complement regulator genes. *Seminars in Thrombosis and Hemostasis*, **2010**, 36, 641-52	5.3	37
110	Polymorphisms of EDNRB, ATG, and ACE genes in salt-sensitive hypertension. *Canadian Journal of Physiology and Pharmacology*, **2008**, 86, 505-10	2.4	37
109	An Ex Vivo Test of Complement Activation on Endothelium for Individualized Eculizumab Therapy in Hemolytic Uremic Syndrome. *American Journal of Kidney Diseases*, **2019**, 74, 56-72	7.4	36
108	Genetic analysis of the complement factor H related 5 gene in haemolytic uraemic syndrome. *Molecular Immunology*, **2007**, 44, 1704-8	4.3	35
107	Thromboxane A2 receptor blocking abrogates donor-specific unresponsiveness to renal allografts induced by thymic recognition of major histocompatibility allopeptides. *Journal of Experimental Medicine*, **1994**, 180, 1967-72	16.6	34
106	Physiology and pathophysiology of nitric oxide in chronic renal disease. *Proceedings of the Association of American Physicians*, **1999**, 111, 602-10		33
105	Peripheral donor leukocytes prolong survival of rat renal allografts. *Kidney International*, **1999**, 56, 1101-12	9.9	30
104	Lack of the lectin-like domain of thrombomodulin worsens Shiga toxin-associated hemolytic uremic syndrome in mice. *Journal of Immunology*, **2012**, 189, 3661-8	5.3	29
103	Adeno-associated virus-mediated CTLA4Ig gene transfer protects MHC-mismatched renal allografts from chronic rejection. *Journal of the American Society of Nephrology: JASN*, **2006**, 17, 1665-72	12.7	29
102	Combined treatment with mycophenolate mofetil and an angiotensin II receptor antagonist fully protects from chronic rejection in a rat model of renal allograft. *Journal of the American Society of Nephrology: JASN*, **2001**, 12, 1937-1946	12.7	29

101	Profiling cancer gene mutations in longitudinal epithelial ovarian cancer biopsies by targeted next-generation sequencing: a retrospective study. *Annals of Oncology*, **2015**, 26, 1363-71	10.3	28
100	Erythropoietin, but not the correction of anemia alone, protects from chronic kidney allograft injury. *Kidney International*, **2012**, 81, 903-18	9.9	28
99	Dendritic cells genetically engineered with adenoviral vector encoding dnIKK2 induce the formation of potent CD4+ T-regulatory cells. *Transplantation*, **2005**, 79, 1056-61	1.8	28
98	Pretransplant donor peripheral blood mononuclear cells infusion induces transplantation tolerance by generating regulatory T cells. *Transplantation*, **2005**, 79, 1034-9	1.8	26
97	Erythropoietin enhances immunostimulatory properties of immature dendritic cells. *Clinical and Experimental Immunology*, **2011**, 165, 202-10	6.2	25
96	Immunophenotypic analysis of cellular infiltrate of renal allograft biopsies in patients with acute rejection after induction with alemtuzumab (Campath-1H). *Clinical Journal of the American Society of Nephrology: CJASN*, **2006**, 1, 539-45	6.9	25
95	ACE inhibition limits chronic injury of kidney transplant even with treatment started when lesions are established. *Kidney International*, **2003**, 64, 2253-61	9.9	25
94	Molecular Basis of Factor H R1210C Association with Ocular and Renal Diseases. *Journal of the American Society of Nephrology: JASN*, **2016**, 27, 1305-11	12.7	24
93	Protein load impairs factor H binding promoting complement-dependent dysfunction of proximal tubular cells. *Kidney International*, **2009**, 75, 1050-9	9.9	24
92	New insights into circulating cell-endothelium interactions and their significance for glomerular pathophysiology. *American Journal of Kidney Diseases*, **1995**, 26, 541-8	7.4	24
91	Urinary excretion of platelet-activating factor in haemolytic uraemic syndrome. *Lancet, The*, **1992**, 339, 835-6	40	24
90	ADAMTS13 predicts renal and cardiovascular events in type 2 diabetic patients and response to therapy. *Diabetes*, **2013**, 62, 3599-609	0.9	23
89	Genetics and genetic testing in hemolytic uremic syndrome/thrombotic thrombocytopenic purpura. *Seminars in Nephrology*, **2010**, 30, 395-408	4.8	23
88	Renal prostacyclin biosynthesis is reduced in children with hemolytic-uremic syndrome in the context of systemic platelet activation. *American Journal of Kidney Diseases*, **1992**, 20, 144-9	7.4	23
87	Thymic microchimerism correlates with the outcome of tolerance-inducing protocols for solid organ transplantation. *Journal of the American Society of Nephrology: JASN*, **2001**, 12, 2815-2826	12.7	23
86	Management of thrombotic microangiopathy in pregnancy and postpartum: report from an international working group. *Blood*, **2020**, 136, 2103-2117	2.2	23
85	Complement Alternative Pathway Deficiency in Recipients Protects Kidney Allograft From Ischemia/Reperfusion Injury and Alloreactive T Cell Response. *American Journal of Transplantation*, **2017**, 17, 2312-2325	8.7	22
84	C5 Convertase Blockade in Membranoproliferative Glomerulonephritis: A Single-Arm Clinical Trial. *American Journal of Kidney Diseases*, **2019**, 74, 224-238	7.4	22

83	17beta-estradiol corrects hemostasis in uremic rats by limiting vascular expression of nitric oxide synthases. *American Journal of Physiology - Renal Physiology*, **2000**, 279, F626-35	4.3	22
82	Complement factor H and hemolytic uremic syndrome. *International Immunopharmacology*, **2001**, 1, 461-88	3.8	22
81	Treatment of Congenital Thrombotic Thrombocytopenic Purpura With Eculizumab. *American Journal of Kidney Diseases*, **2015**, 66, 1067-70	7.4	21
80	Both darbepoetin alfa and carbamylated erythropoietin prevent kidney graft dysfunction due to ischemia/reperfusion in rats. *Transplantation*, **2011**, 92, 271-9	1.8	21
79	Immunomodulatory effects of mesenchymal stromal cells in solid organ transplantation. *Current Opinion in Organ Transplantation*, **2010**, 15, 731-7	2.5	21
78	Translational mini-review series on complement factor H: therapies of renal diseases associated with complement factor H abnormalities: atypical haemolytic uraemic syndrome and membranoproliferative glomerulonephritis. *Clinical and Experimental Immunology*, **2008**, 151, 199-209	6.2	21
77	Autoimmune abnormalities of the alternative complement pathway in membranoproliferative glomerulonephritis and C3 glomerulopathy. *Pediatric Nephrology*, **2019**, 34, 1311-1323	3.2	20
76	Natural versus adaptive regulatory T cells. *Contributions To Nephrology*, **2005**, 146, 121-131	1.6	20
75	alpha 1-Antitrypsin therapy in a case of thrombotic thrombocytopenic purpura. *Lancet, The*, **1995**, 345, 224-5	40	20
74	The state of complement in COVID-19.. *Nature Reviews Immunology*, **2021**,	36.5	20
73	Factor H Competitor Generated by Gene Conversion Events Associates with Atypical Hemolytic Uremic Syndrome. *Journal of the American Society of Nephrology: JASN*, **2018**, 29, 240-249	12.7	19
72	DnIKK2-transfected dendritic cells induce a novel population of inducible nitric oxide synthase-expressing CD4+CD25- cells with tolerogenic properties. *Transplantation*, **2007**, 83, 474-84	1.8	19
71	Liver transplantation for aHUS: still needed in the eculizumab era?. *Pediatric Nephrology*, **2016**, 31, 759-68	3.2	18
70	Nitric oxide synthetic capacity in relation to dialysate temperature. *Blood Purification*, **2004**, 22, 203-9	3.1	17
69	Nitric oxide/L-arginine in uremia. *Mineral and Electrolyte Metabolism*, **1999**, 25, 384-90		17
68	Methylprednisolone dosage effects on peripheral lymphocyte subpopulations and eicosanoid synthesis. *Kidney International*, **1992**, 42, 981-90	9.9	17
67	Urinary excretion of platelet activating factor in patients with immune-mediated glomerulonephritis. *Kidney International*, **1993**, 43, 426-9	9.9	17
66	Genetic abnormalities of complement regulators in hemolytic uremic syndrome: how do they affect patient management?. *Nature Clinical Practice Nephrology*, **2005**, 1, 2-3		16

65	In-vitro and in-vivo consequences of mutations in the von Willebrand factor cleaving protease ADAMTS13 in thrombotic thrombocytopenic purpura. *Thrombosis and Haemostasis*, **2006**, 96, 454-64	7	16
64	Rare Functional Variants in Complement Genes and Anti-FH Autoantibodies-Associated aHUS. *Frontiers in Immunology*, **2019**, 10, 853	8.4	15
63	Unraveling the Molecular Mechanisms Underlying Complement Dysregulation by Nephritic Factors in C3G and IC-MPGN. *Frontiers in Immunology*, **2018**, 9, 2329	8.4	15
62	Prolonged cold ischemia accelerates cellular and humoral chronic rejection in a rat model of kidney allotransplantation. *Transplant International*, **2012**, 25, 347-56	3	14
61	Rabbit anti-rat thymocyte immunoglobulin preserves renal function during ischemia/reperfusion injury in rat kidney transplantation. *Transplant International*, **2011**, 24, 829-38	3	14
60	Genetics of Immune-Mediated Glomerular Diseases: Focus on Complement. *Seminars in Nephrology*, **2017**, 37, 447-463	4.8	13
59	Increased urinary excretion of platelet activating factor in mice with lupus nephritis. *Life Sciences*, **1991**, 48, 1429-37	6.8	13
58	Peripheral donor leukocytes prolong survival of rat renal allografts. *Kidney International*, **1999**, 56, 1101	9.9	13
57	A novel antibody against human factor B that blocks formation of the C3bB proconvertase and inhibits complement activation in disease models. *Journal of Immunology*, **2014**, 193, 5567-75	5.3	12
56	Discordant phenotype in monozygotic twins with renal coloboma syndrome and a PAX2 mutation. *Pediatric Nephrology*, **2012**, 27, 1989-93	3.2	12
55	Klotho in acute kidney injury: biomarker, therapy, or a bit of both?. *Kidney International*, **2010**, 78, 1208-10	9.9	12
54	Single Strand Conformation Polymorphism (SSCP) as a quick and reliable method to genotype M235T polymorphism of angiotensinogen gene. *Clinical Biochemistry*, **2002**, 35, 363-8	3.5	12
53	Insights into the Effects of Complement Factor H on the Assembly and Decay of the Alternative Pathway C3 Proconvertase and C3 Convertase. *Journal of Biological Chemistry*, **2016**, 291, 8214-30	5.4	11
52	Non-muscle myosins and the podocyte. *CKJ: Clinical Kidney Journal*, **2012**, 5, 94-101	4.5	11
51	Thrombotic microangiopathies: from animal models to human disease and cure. *Contributions To Nephrology*, **2011**, 169, 337-350	1.6	10
50	ADAMTS13 Secretion and Residual Activity among Patients with Congenital Thrombotic Thrombocytopenic Purpura with and without Renal Impairment. *Clinical Journal of the American Society of Nephrology: CJASN*, **2015**, 10, 2002-12	6.9	9
49	An unanticipated role for survivin in organ transplant damage. *American Journal of Transplantation*, **2014**, 14, 1046-60	8.7	9
48	ACE inhibitors and AT1 receptor antagonists: is two better than one?. *Kidney International*, **2002**, 61, 1545-7	9.9	9

47	Effect of Timing and Complement Receptor Antagonism on Intragraft Recruitment and Protolerogenic Effects of Mesenchymal Stromal Cells in Murine Kidney Transplantation. *Transplantation*, **2019**, 103, 1121-1130	1.8	9
46	Immunochip analysis identifies novel susceptibility loci in the human leukocyte antigen region for acquired thrombotic thrombocytopenic purpura. *Journal of Thrombosis and Haemostasis*, **2016**, 14, 2356-2367	15.4	8
45	Embryonic stem cells, derived either after in vitro fertilization or nuclear transfer, prolong survival of semiallogeneic heart transplants. *Journal of Immunology*, **2011**, 186, 4164-74	5.3	8
44	Impact of a Complement Factor H Gene Variant on Renal Dysfunction, Cardiovascular Events, and Response to ACE Inhibitor Therapy in Type 2 Diabetes. *Frontiers in Genetics*, **2019**, 10, 681	4.5	7
43	Reduced nitric oxide bioavailability in a baboon model of Shiga toxin mediated hemolytic uremic syndrome (HUS). *Renal Failure*, **2005**, 27, 635-41	2.9	7
42	C5a and C5aR1 are key drivers of microvascular platelet aggregation in clinical entities spanning from aHUS to COVID-19. *Blood Advances*, **2021**,	7.8	7
41	Propionyl-L-carnitine prevents early graft dysfunction in allogeneic rat kidney transplantation. *Kidney International*, **2008**, 74, 1420-8	9.9	6
40	Complement factor h gene abnormalities in haemolytic uraemic syndrome: from point mutations to hybrid gene. *PLoS Medicine*, **2006**, 3, e432	11.6	6
39	Identification of a novel gene--SSK1--in human endothelial cells exposed to shear stress. *Biochemical and Biophysical Research Communications*, **1998**, 246, 881-7	3.4	6
38	Transplantation-Induced Ischemia-Reperfusion Injury Modulates Antigen Presentation by Donor Renal CD11cF4/80 Macrophages through IL-1R8 Regulation. *Journal of the American Society of Nephrology: JASN*, **2020**, 31, 517-531	12.7	5
37	Terminal complement effectors in atypical hemolytic uremic syndrome: C5a, C5b-9, or a bit of both?. *Kidney International*, **2019**, 96, 13-15	9.9	5
36	More about Factor H Autoantibodies in Membranous Nephropathy. *New England Journal of Medicine*, **2019**, 381, 1590-1592	59.2	5
35	Toward a B-cell signature of tolerance?. *Kidney International*, **2010**, 78, 435-7	9.9	5
34	Are HUS and TTP genetically determined?. *Kidney International*, **1998**, 53, 1085-6	9.9	5
33	Effect of seliciclib (CYC202, R-roscovitine) on lymphocyte alloreactivity and acute kidney allograft rejection in rat. *Transplantation*, **2008**, 85, 1476-82	1.8	5
32	IgA nephropathy: a stem cell disease?. *Kidney International*, **1999**, 56, 1964-6	9.9	5
31	Atypical hemolytic uremic syndrome associated with a factor B genetic variant and fluid-phase complement activation: an exception to the rule?. *Kidney International*, **2020**, 98, 1084-1087	9.9	5
30	Genetic testing in the diagnosis of chronic kidney disease: recommendations for clinical practice. *Nephrology Dialysis Transplantation*, **2021**,	4.3	5

29	Posttransplant recurrence of atypical hemolytic uremic syndrome. *Journal of Nephrology*, **2012**, 25, 911-7	4.8	4
28	Autotaxin Inhibitor Protects from Chronic Allograft Injury in Rat Kidney Allotransplantation. *Nephron*, **2020**, 144, 38-48	3.3	4
27	Eculizumab in patients with severe coronavirus disease 2019 (COVID-19) requiring continuous positive airway pressure ventilator support: Retrospective cohort study.. *PLoS ONE*, **2021**, 16, e0261113	3.7	4
26	Molecular Studies and an Complement Assay on Endothelium Highlight the Genetic Complexity of Atypical Hemolytic Uremic Syndrome: The Case of a Pedigree With a Null CD46 Variant. *Frontiers in Medicine*, **2020**, 7, 579418	4.9	3
25	Role of thymic- and graft-dependent mechanisms in tolerance induction to rat kidney transplant by donor PBMC infusion. *Kidney International*, **2007**, 71, 1132-41	9.9	3
24	Membranoproliferative glomerulonephritis: no longer the same disease and may need very different treatment. *Nephrology Dialysis Transplantation*, **2021**,	4.3	3
23	Association of CFHR1 homozygous deletion with acute myelogenous leukemia in the European population. *Leukemia and Lymphoma*, **2016**, 57, 1234-7	1.9	2
22	Effect of a novel immunosuppressant, ST1959, on the immune system and renal allograft survival in rats. *Transplantation*, **2005**, 80, 231-6	1.8	2
21	Diverse Functional Implications of ADAMTS13 Gene Mutations in Patients with TTP and Congenital Deficiency.. *Blood*, **2004**, 104, 513-513	2.2	2
20	Thrombotic microangiopathy without renal involvement: two novel mutations in complement-regulator genes. *Journal of Thrombosis and Haemostasis*, **2016**, 14, 340-5	15.4	2
19	Non-Shiga toxin-associated hemolytic uremic syndrome **2006**, 65-83		2
18	Hemolytic Uremic Syndrome in an Infant with Primary Hyperoxaluria Type II: An Unreported Clinical Association. *Nephron*, **2019**, 142, 264-270	3.3	1
17	Thrombotic microangiopathies **2012**, 278-282		1
16	Defective glomerular [3H]lysoPAF metabolism in the autologous phase of rabbit nephrotoxic nephritis. *Kidney International*, **1993**, 44, 747-54	9.9	1
15	Increased Fragmentation of von Willebrand Factor, Due to Abnormal Cleavage of the Subunit, Parallels Disease Activity in Recurrent Hemolytic Uremic Syndrome and Thrombotic Thrombocytopenic Purpura and Discloses Predisposition in Families. *Blood*, **1999**, 94, 610-620	2.2	1
14	and Copy Number Variations in C3 Glomerulopathy and Immune Complex-Mediated Membranoproliferative Glomerulonephritis. *Frontiers in Genetics*, **2021**, 12, 670727	4.5	1
13	The case of complement inhibitors. *Advances in Biological Regulation*, **2021**, 81, 100822	6.2	1
12	Kidney transplantation from a donor with acute kidney injury: an unexpected outcome. *American Journal of Transplantation*, **2014**, 14, 977-8	8.7	0

11	Amnion epithelial cells are an effective source of factor H and prevent kidney complement deposition in factor H-deficient mice. *Stem Cell Research and Therapy*, **2021**, 12, 332	8.3	0
10	Case Report: Effects of Anti-SARS-CoV-2 Convalescent Antibodies Obtained With Double Filtration Plasmapheresis. *Frontiers in Immunology*, **2021**, 12, 711915	8.4	0
9	Hemolytic Uremic Syndrome **2019**, 294-301.e2		
8	Chapter 14 Hemolytic Uremic Syndrome/Thrombotic Thrombocytopenic Purpura. *Handbook of Systemic Autoimmune Diseases*, **2007**, 257-282	0.3	
7	Donor hematopoietic cells: central versus peripheral tolerance. *Current Opinion in Organ Transplantation*, **2004**, 9, 284-288	2.5	
6	Induction of Tolerance in Allotransplantation **2007**, 461-474		
5	ATYPICAL HEMOLYTIC UREMIC SYNDROME AND C3 GLOMERULOPATHY: CONCLUSIONS FROM A "KIDNEY DISEASE: IMPROVING GLOBAL OUTCOMES" (KDIGO) CONTROVERSIES CONFERENCE. *Nephrology (Saint-Petersburg)*, **2018**, 22, 18-39	0.4	
4	A Putative Role of NO and Oxidant Injury in the Pathogenesis of Hemolytic Uremic Syndrome **1997**, 418-427		
3	Nitric oxide as a mediator of hemodynamic disturbances in acute renal failure associated with sepsis **1998**, 575-589		
2	Hemolytic Uremic Syndrome/Thrombotic Thrombocytopenic Purpura **2010**, 349-364		
1	Residual Plasmatic Activity of ADAMTS13 in Congenital Thrombotic Thrombocytopenic Purpura Correlates with Disease Phenotype. *Blood*, **2011**, 118, 2219-2219	2.2	